# Efficacy of Using Solum IV and BMC With GFC in TLIF

> **NCT03223701** · PHASE4 · WITHDRAWN · sponsor: **Seton Healthcare Family**

## Conditions studied

- Degenerative Disc Disease
- Isthmic-lytic Spondylolisthesis
- Degenerative Spondylolisthesis
- Spinal Stenosis

## Interventions

- **COMBINATION_PRODUCT:** Solum IV, Bone Marrow Concentrate with general fluid concentrate (GFC) in Transforaminal Lumbar Interbody Fusion

## Key facts

- **NCT ID:** NCT03223701
- **Lead sponsor:** Seton Healthcare Family
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-09-30
- **Primary completion:** 2018-09-30
- **Final completion:** 2018-12-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was never initiated due to contracting issues
- **Last updated:** 2018-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03223701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03223701, "Efficacy of Using Solum IV and BMC With GFC in TLIF". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03223701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*